Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - nitisinone, quantity: 5 mg - capsule, hard - excipient ingredients: gelatin; titanium dioxide; pregelatinised maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - nitisinone, quantity: 2 mg - capsule, hard - excipient ingredients: titanium dioxide; gelatin; pregelatinised maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - nitisinone 10mg - capsule - 10 mg - active: nitisinone 10mg excipient: gelatin starch stearic acid titanium dioxide - indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - nitisinone 2mg - capsule - 2 mg - active: nitisinone 2mg excipient: gelatin starch stearic acid titanium dioxide - indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - nitisinone 5mg - capsule - 5 mg - active: nitisinone 5mg excipient: gelatin starch stearic acid titanium dioxide - indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine.

Australia - English - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - nitisinone, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; glycerol dibehenate - nityr tablets (nitisinone) are indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australia - English - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - nitisinone, quantity: 2 mg - tablet - excipient ingredients: lactose monohydrate; glycerol dibehenate - nityr tablets (nitisinone) are indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australia - English - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - nitisinone, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; glycerol dibehenate - nityr tablets (nitisinone) are indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dipharma arzneimittel gmbh - nitisinone 5 mg - capsule, hard - 5 mg - nitisinone 5 mg - nitisinone

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dipharma arzneimittel gmbh - nitisinone 10 mg - capsule, hard - 10 mg - nitisinone 10 mg - nitisinone